{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:41:27Z","timestamp":1792712487835,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RG-1606\\u201308768"],"award-info":[{"award-number":["RG-1606\\u201308768"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["08768"],"award-info":[{"award-number":["08768"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RG-1606"],"award-info":[{"award-number":["RG-1606"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23 EY 024345"],"award-info":[{"award-number":["K23 EY 024345"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 EY 026877"],"award-info":[{"award-number":["P30 EY 026877"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015537","name":"Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS082347"],"award-info":[{"award-number":["R01NS082347"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS113828"],"award-info":[{"award-number":["R01NS113828"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["K23NS117883"],"award-info":[{"award-number":["K23NS117883"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.msard.2022.103525","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T21:15:09Z","timestamp":1641849309000},"page":"103525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"special_numbering":"C","title":["OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis"],"prefix":"10.1016","volume":"58","author":[{"given":"John J.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias S.","family":"Sotirchos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda D.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni S.","family":"Vasileiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin P.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Tariq","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Jamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Eggenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Dinome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry P.","family":"Frohman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Seleme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro J.","family":"Mejia-Vergara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanyatuth","family":"Padungkiatsagul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Stiebel-Kalish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itay","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Hodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederike Cosima","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv","family":"Saidha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.msard.2022.103525_bib0037","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/IJG.0b013e318255bb4a","article-title":"Analysis of normal retinal nerve fiber layer thickness by age, sex, and race using spectral domain optical coherence tomography","volume":"22","author":"Alasil","year":"2013","journal-title":"J. Glaucoma"},{"issue":"9","key":"10.1016\/j.msard.2022.103525_bib0028","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.msard.2022.103525_bib0019","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s00415-017-8615-8","article-title":"Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France","volume":"264","author":"Biotti","year":"2017","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.103525_bib0039","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1093\/brain\/awy245","article-title":"Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study","volume":"141","author":"Caldito","year":"2018","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2022.103525_bib0018","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis","volume":"33","author":"Chen","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2022.103525_bib0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody\u2013Positive Optic Neuritis: clinical Characteristics, Radiologic Clues, and Outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.msard.2022.103525_bib0029","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","article-title":"Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial","volume":"136","author":"Chen","year":"2018","journal-title":"JAMA Ophthalmol."},{"issue":"2","key":"10.1016\/j.msard.2022.103525_bib0034","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2022.103525_bib0044","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.survophthal.2019.08.001","article-title":"Optic neuritis in the era of biomarkers","volume":"65","author":"Chen","year":"2020","journal-title":"Surv. Ophthalmol."},{"issue":"21","key":"10.1016\/j.msard.2022.103525_bib0005","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"24","key":"10.1016\/j.msard.2022.103525_bib0024","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1212\/WNL.0000000000002774","article-title":"The APOSTEL recommendations for reporting quantitative optical coherence tomography studies","volume":"86","author":"Cruz-Herranz","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103525_bib0031","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.msard.2018.10.013","article-title":"Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: clinical course and treatment outcome","volume":"27","author":"Etemadifar","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2022.103525_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.540156","article-title":"AQP4-IgG and MOG-IgG Related Optic Neuritis-Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: a Systematic Review and Meta-Analysis","volume":"11","author":"Filippatou","year":"2020","journal-title":"Front Neurol"},{"issue":"21","key":"10.1016\/j.msard.2022.103525_bib0043","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1212\/WNL.0000000000005619","article-title":"Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder","volume":"90","author":"Hacohen","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103525_bib0014","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajo.2020.07.014","article-title":"Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies","volume":"220","author":"Hassan","year":"2020","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.msard.2022.103525_bib0004","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.msard.2022.103525_bib0006","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.msard.2022.103525_bib0002","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12974-018-1108-6","article-title":"MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.msard.2022.103525_bib0008","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.msard.2022.103525_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2018.03.041","article-title":"Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis","author":"Jitprapaikulsan","year":"2018","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.msard.2022.103525_bib0003","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.msard.2022.103525_bib0033","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10384-018-0561-1","article-title":"Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis","volume":"62","author":"Kezuka","year":"2018","journal-title":"Jpn. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.msard.2022.103525_bib0036","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ophtha.2011.10.010","article-title":"Retinal nerve fiber layer imaging with spectral-domain optical coherence tomography: a prospective analysis of age-related loss","volume":"119","author":"Leung","year":"2012","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.msard.2022.103525_bib0020","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders","volume":"75","author":"Lopez-Chiriboga","year":"2018","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.103525_bib0040","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1167\/iovs.10-5222","article-title":"Reproducibility of peripapillary retinal nerve fiber layer thickness and optic nerve head parameters measured with cirrus HD-OCT in glaucomatous eyes","volume":"51","author":"Mwanza","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.msard.2022.103525_bib0041","article-title":"Quiescent MRI activity in neuromyelitis optica spectrum disorder: results from the N-MOmentum randomized placebo-controlled trial","author":"Paul","year":"2020","journal-title":"Abstract ECTRIMS - ACTRIMS"},{"issue":"6","key":"10.1016\/j.msard.2022.103525_bib0042","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1055\/s-0039-3399505","article-title":"What You Need to Know About AQP4, MOG, and NMOSD","volume":"39","author":"Prasad","year":"2019","journal-title":"Semin. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2022.103525_bib0027","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2022.103525_bib0030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.msard.2022.103525_bib0009","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WCO.0000000000000446","article-title":"Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they?","volume":"30","author":"Reindl","year":"2017","journal-title":"Curr. Opin. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.103525_bib0012","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.msard.2022.103525_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing","author":"Sechi","year":"2021","journal-title":"JAMA Neurol."},{"issue":"14","key":"10.1016\/j.msard.2022.103525_bib0016","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1177\/1352458517734070","article-title":"A population-based prospective study of optic neuritis","volume":"23","author":"Soelberg","year":"2017","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/j.msard.2022.103525_bib0026","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1177\/1352458519864928","article-title":"Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning","volume":"26","author":"Sotirchos","year":"2020","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2022.103525_bib0038","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ana.25738","article-title":"Progressive Multiple Sclerosis Is Associated with Faster and Specific Retinal Layer Atrophy","volume":"87","author":"Sotirchos","year":"2020","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2022.103525_bib0032","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"10.1016\/j.msard.2022.103525_bib0011","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11910-019-1014-z","article-title":"Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis","volume":"19","author":"Tajfirouz","year":"2019","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"4","key":"10.1016\/j.msard.2022.103525_bib0023","doi-asserted-by":"crossref","first-page":"e34823","DOI":"10.1371\/journal.pone.0034823","article-title":"The OSCAR-IB consensus criteria for retinal OCT quality assessment","volume":"7","author":"Tewarie","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.msard.2022.103525_bib0022","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.103525_bib0021","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103525_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418762083","article-title":"Defining distinct features of anti-MOG antibody associated central nervous system demyelination","volume":"11","author":"Weber","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.msard.2022.103525_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.msard.2022.103525_bib0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.msard.2022.103525_bib0017","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/bjophthalmol-2017-311177","article-title":"Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients","volume":"102","author":"Zhao","year":"2018","journal-title":"Br. J. Ophthalmol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822000402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822000402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:28:20Z","timestamp":1778840900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822000402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":44,"alternative-id":["S2211034822000402"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103525","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103525"}}